Limited Offer
Cancer Epigenetics and Nanomedicine
Targeting the Right Player via Nanotechnology
- 1st Edition - June 26, 2024
- Editors: Prashant Kesharwani, Chitra Thakur
- Language: English
- Paperback ISBN:9 7 8 - 0 - 4 4 3 - 1 3 2 0 9 - 4
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 1 3 2 1 0 - 0
Cancer Epigenetics and Nanomedicine: Targeting the Right Player via Nanotechnology is a complete package that provides a comprehensive and thorough understanding of the key player… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteSince epigenetic aberrations can be potentially reversed and restored to their normal state through epigenetic therapy, the book also discusses the challenges and the future of the field with the cutting-edge revelations and limitations that this research endeavor can offer, thereby helping the readers to enhance their critical thinking and adopt strategies of therapeutic importance.
• Provides in-depth knowledge on epigenetics and the various epigenetic biomolecules, enzymes, and other signaling pathways that are promising entities for drug discovery and chemotherapeutics
• Presents state-of-the-art information on the next-generation cancer therapies, challenges, and future of the field
- Cover image
- Title page
- Table of Contents
- Copyright
- Dedication
- Contributors
- About the editors
- Preface
- Acknowledgments
- Section 1: Overview of cancer, internal and external factors associated with cancer
- Chapter 1 Overview of cancer: Mechanisms of carcinogenesis
- Abstract
- Introduction
- Cancer: A historical perspective
- Origin of cancer: Theories and drivers of carcinogenesis
- Hallmarks of cancer
- Epigenetics and cancer
- Conclusion
- References
- Chapter 2 Tumor metabolism and micronutrients: New insights to target malignant tumors
- Abstract
- Introduction
- Role of micronutrients in targeting malignant tumors
- Impact of iron levels on cancer proliferation
- Targeting intracellular iron levels to induce cellular death
- Impact of calcium levels on cancer proliferation
- Targeting calcium levels to induce cellular death
- Impact of magnesium levels on cancer proliferation
- Targeting Warburg effect to induce tumor cell death
- Role of glycolytic enzymes in inducing cancer cell death
- Other metabolic pathways used by tumor cells
- Interplay between glutaminolysis and Warburg effect
- Discussion and conclusion
- References
- Chapter 3 The role of one-carbon amino acids in tumor-immune metabolism: From oncogenesis to therapy
- Abstract
- Introduction
- One-carbon metabolism
- One-carbon metabolism and T-cell function
- Restriction of AAs as therapy
- Conclusion and future directions
- References
- Chapter 4 Environmental causes of cancer
- Abstract
- Introduction
- Perspectives
- References
- Chapter 5 Cancer stem cells—Challenges for cancer therapies
- Abstract
- Introduction
- The identification of the CSCs
- CSCs in tumorigenesis models
- Biology of CSCs
- Challenges posed by CSCs in cancer therapies
- Perspective
- References
- Chapter 6 Carving a therapeutic niche for metastatic cancer: Opportunities and challenges
- Abstract
- Introduction
- Conclusion
- References
- Section 2: Epigenetics and its importance in cancer therapies
- Chapter 7 An overview of epigenetics and cancer
- Abstract
- Role of epigenetics in normal and cancer cells
- Epigenetics mechanism and their regulation on cancer
- DNA methylation and histone methylation cross-talks
- Role of epigenetic dysregulation of noncoding RNAs in cancer
- Epigenetic dysregulation in cancer stem cells, a promise for therapeutic intervention
- Epigenetics in the clinics: Prognostics, diagnostics, and therapeutic intervention for cancers
- Advancements and innovation in epigenetic technologies in investigating mechanisms in cancer cells
- References
- Chapter 8 Metabolic adaptation and epigenetic modulations: Unraveling tumor plasticity under variable tumor microenvironment
- Abstract
- Introduction
- Metabolic adaptation to TME
- Epigenetic and metabolic crosstalk in TME
- Epigenetic modifications in shaping the TME
- References
- Chapter 9 Involvement of epigenetic modifications in cancer stem cells and chemoresistance
- Abstract
- Tumor heterogeneity and drug resistance
- Cancer stem cells: A new dimension to drug resistance
- Reprogramming of cancer stem cells and epigenetic modifications
- DNA methylation
- Histone modifications
- Noncoding RNAs
- RNA methylation
- Epigenetic involvement in drug resistance
- Therapeutic targeting of epigenetic alterations in cancers
- References
- Chapter 10 Cancer biomarkers: Where genetics meets epigenetics
- Abstract
- Epigenetics in cancer biology
- Histone modifications
- DNA methylation
- Chromatin remodeling complexes
- Noncoding RNAs
- Conclusion
- References
- Chapter 11 Epigenetics approach in cancer treatment with focus on lung and breast cancer
- Abstract
- Introduction to epigenetics in breast and lung cancer
- DNA methylation in breast and lung cancer
- Chromatin remodeling and HDAC inhibition
- Role of miRNAs as epigenetic biomarkers
- Scope of epidrugs
- Future directions
- References
- Chapter 12 Dietary components as epigenetic modifiers and their roles in cancer prevention
- Abstract
- Introduction
- Epigenetic mechanisms and its importance in cancer
- Crosstalk between dietary components and metabolism in epigenetic regulation
- Types of dietary components and their role in epigenetics and chemoprevention
- Dietary polyphenols
- Epigallocatechin-gallate
- Sulforaphane
- Resveratrol
- Curcumin
- Quercetin
- Genistein
- Conclusion
- References
- Section 3: Nanomedicine targeting epigenetic machinery in cancer therapy
- Chapter 13 Harnessing plant-derived biosynthetic nanomaterials for epigenetic modulation in cancer therapy
- Abstract
- Introduction
- Epigenetic modulation in cancer
- Biosynthetic nanomaterials from plants
- Epigenetic modulation by biosynthetic nanomaterials
- Experimental evidence and preclinical studies
- Clinical potential and future directions
- Conclusion
- References
- Chapter 14 Nanotechnology-enhanced immunotherapy for cancer
- Abstract
- Introduction
- The fundamentals of the immune system
- T-cell ontogeny
- T-cell activation signals
- Tumor immunology
- Adoptive T-cell therapy for combating cancers
- Immune checkpoints and their role in cancer immunotherapy
- Nanotechnological advances in immunotherapy
- References
- Chapter 15 Nanoparticles in metastatic cancer treatment
- Abstract
- Acknowledgments
- Introduction
- Understanding metastasis in cancer
- NPs for drug delivery
- Targeted drug delivery methodologies
- Applications in metastatic cancer treatment
- Conclusion and future perspectives
- References
- Chapter 16 Amine-terminated dendrimers: A novel method for diagnose, control and treatment of cancer
- Abstract
- Introduction
- A summary of amine-terminated dendrimers
- The application of amine-terminated dendrimers in cancer
- Toxicity of dendrimers
- Conclusion and future trend
- References
- Chapter 17 Nanomedicine and epigenome: Possible health risks, benefits, and future perspectives
- Abstract
- Introduction
- Therapeutic implications of nanomaterial in nanomedicine
- Potential role of epigenetics in nanomedicine
- Types of epigenetic modifications
- Role of epigenetic alterations in the safety assessment of nanomaterials
- Conclusion and future perspectives
- References
- Chapter 18 Smart cancer nanomedicine: Challenges and future opportunities
- Abstract
- Acknowledgments
- Introduction
- Smart GSH, ROS, and Hypoxia-sensitive nanoparticles
- Enzyme-responsive nanomaterials
- Conclusion
- References
- Index
- No. of pages: 550
- Language: English
- Edition: 1
- Published: June 26, 2024
- Imprint: Academic Press
- Paperback ISBN: 9780443132094
- eBook ISBN: 9780443132100
PK
Prashant Kesharwani
Dr. Prashant Kesharwani is an assistant professor of pharmaceutics at School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India. He has more than 12 years of teaching, research, and industrial experience at international levels from various countries, including the United States, Malaysia, and India. An overarching goal of his current research is the development of nanoengineered drug delivery systems for various diseases. He has more than 300 international publications in well-reputed journals and more than 25 international books (Elsevier). He is a recipient of many research grants from various funding bodies. He is also the recipient of several internationally acclaimed awards, such as “USERN Laureate award”, most prestigious “Ramanujan Fellowship Award”. He actively participates in outreach and scientific dissemination for the service of the wider community.
CT
Chitra Thakur
Dr. Chitra Thakur is an Assistant Professor-Research in the Department of Pathology at the Stony Brook Cancer Center, New York, USA. She is a cancer biologist and has expertise in molecular oncology, mouse models of human cancers, analyzing big data in translational research, toxicology, and epigenetics in human cancers. She is the recipient of several internationally acclaimed awards such as the “DFG German Excellence Initiative Award,”, “NIH-Big Data Training for Translational Omics Research” and “American Cancer Society IRG”. With more than 45 research articles published in mainstream scientific journals, she has contributed significantly towards the understanding of the molecular mechanisms in human cancers. She is engrossed in cancer research, teaching, and community outreach initiatives, hence fostering the scientific community and health care professionals engaged in cancer diagnosis, and treatment.